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Abstract
Background: Harmaline and harmine are tremorigenic b-carbolines that, on administration to experimental animals, induce an acute postural and kinetic tremor
of axial and truncal musculature. This drug-induced action tremor has been proposed as a model of essential tremor. Here we review what is known about
harmaline tremor.
Methods: Using the terms harmaline and harmine on PubMed, we searched for papers describing the effects of these b-carbolines on mammalian tissue, animals,
or humans.
Results: Investigations over four decades have shown that harmaline induces rhythmic burst-firing activity in the medial and dorsal accessory inferior olivary
nuclei that is transmitted via climbing fibers to Purkinje cells and to the deep cerebellar nuclei, then to brainstem and spinal cord motoneurons. The critical
structures required for tremor expression are the inferior olive, climbing fibers, and the deep cerebellar nuclei; Purkinje cells are not required. Enhanced synaptic
norepinephrine or blockade of ionic glutamate receptors suppresses tremor, whereas enhanced synaptic serotonin exacerbates tremor. Benzodiazepines and
muscimol suppress tremor. Alcohol suppresses harmaline tremor but exacerbates harmaline-associated neural damage. Recent investigations on the mechanism of
harmaline tremor have focused on the T-type calcium channel.
Discussion: Like essential tremor, harmaline tremor involves the cerebellum, and classic medications for essential tremor have been found to suppress harmaline
tremor, leading to utilization of the harmaline model for preclinical testing of antitremor drugs. Limitations are that the model is acute, unlike essential tremor, and
only approximately half of the drugs reported to suppress harmaline tremor are subsequently found to suppress tremor in clinical trials.
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Introduction
Harmaline induces action tremor in mammals, and as an easily
elicited model has attracted increasing interest from workers searching
for new therapies for essential tremor (ET). In view of this interest, we
review what is known about harmaline’s actions. We describe the
model and review the anatomy and physiology of the olivocerebellar
circuitry underlying harmaline tremor. We consider proposed
mechanisms by which harmaline produces tremor and survey the
pharmacology of harmaline tremor. We discuss the limitations of the
model and consider how well harmaline predicts drug efficacy for ET.
Methods
We surveyed literature obtained via PubMed using the search words
‘‘harmaline’’ and ‘‘harmine’’, examining papers describing mechanisms,
properties, or tremor. We also consulted related papers on cerebellum
physiology and ET. Only a fraction of these publications could be cited.
Results
b-Carbolines
The basic structure of b-carboline alkaloids is similar to tryptamine,
a two-ring indole, but the ethylamine side chain is reconnected to the
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indole via a carbon atom, forming a third ring. b-Carbolines differ
according to the degree of saturation of the third ring, the third ring
side chain, and the side chains on the benzene ring (Figure 1).
Nutritionally the main source of b-carbolines is animal protein, but
they are also found in cereals, corn, beverages (wine, whiskey, beer,
sake), and in tobacco.1 b-Carbolines are also formed endogenously
from the condensation of tryptophan-derived indolealkylamines with
simple aldehydes or with pyruvic acid. Thus some b-carbolines, such
as harmane and norharman, are normal constituents of human tissue.
Because ethanol is converted to aldehyde in tissues and in the
stomach,2 a question is whether alcohol ingestion elevates b-carboline
levels. Rats chronically administered alcohol display elevated plasma
and brain norharman,3 but no change in brain or lung harmane.4 In
humans, elevated plasma norharman is associated with heavy smoking
rather than alcohol intake.5
The rate of elimination also affects b-carboline levels. In humans, CYP
1A2 and 2D6 are the major cytochrome enzymes metabolizing
harmaline and harmine, converting these by O-demethylation to non-
tremorigenic harmalolol and harmol.6 Human Purkinje cells express
2D6, and this expression is upregulated in alcoholics.7 Smoking also
increases 2D6 expression in the human brain, as does nicotine
administration in animals.8 Cytochrome 2D6 may play a role in
defending against b-carboline derivatives that have potential 1-methyl-4-
phenylpyridine (MPP)-like neurotoxicity. Endogenous tetrahydro-b-
carbolines can undergo methylation by N-methyltransferases to form
N(2)-methyl- and N(2,9)-dimethyl-tetrahydro-b-carbolines, which are
similar to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).9 Such
compounds are found in rat brain and are oxidized by heme oxidases to
the corresponding b-carboliniums, structurally analogous to MPP+,10
and similarly neurotoxic. N(2)- and N(9)-methylnorharmanium ions
induce bradykinesia and dopamine loss in mice.11 As an alternative
to forming b-carbolinium products, N-methylated b-carbolines are
removed by CYP 2D6, at a rate highly dependent on the 2D6
polymorphism subtype.12
Such observations have led to speculation that brain 2D6 may
protect against neurotoxins derived from b-carbolines or other toxins,
in view of evidence that smoking protects against Parkinson’s and
ET.13 However, persons who inherit a 2D6 polymorphism with low
activity have an inconsistent or weak increase in risk for Parkinson’s
disease.14
Do b-carbolines cause ET? ET patients have higher harmane blood
levels, especially in familial cases,15 which is not due to higher dietary
intake.16 Harmane in high doses may cause tremor,17 or do so via a
metabolite, harmine. A role of harmane could also be from tissue
damage that gives rise to tremor. Indeed, among ET patients, blood
harmane levels are significantly correlated with the decline in a
spectroscopic magnetic resonance imaging measure of viable neurons
in the cerebellar cortex.18
Harmaline tremor: an acute model
The harmala alkaloids harmine, harmaline, and tetrahydroharmine
are especially rich in the seeds of Peganum harmala (Syrian Rue) and in
the Banisteriopsis caapi vine. Extracts from the latter are combined with
leaves from Psychotria viridis, containing dimethyltryptamine (DMT), to
create the ayahuasca sacramental beverage used in shamanic rituals.
The principal purpose of the harmala compounds is to inactivate
gastrointestinal monoamine oxidase (MAO-A), enabling enough DMT
to elude first-pass metabolism so as to produce cognitive/affective
effects. The amount of harmala alkaloids absorbed may be small or
negligible.19 Large doses of harmine or preparations of B. caapi induce
in human volunteers a transient coarse tremor.20
Among b-carbolines, ibogaine, harmaline and harmine are
especially tremorigenic. Of these, harmaline (7-methoxy-3.4-dihydro-
b-carboline) has been most frequently utilized experimentally, but
harmine acts similarly, and similar doses are employed. Harmaline
produces an 8–16 Hz tremor in mice,21 rats, cats,22 and monkeys.23
The tremor involves appendicular and axial musculature during
posture and kinesis. In a mouse or rat the tremor visibly involves all
four limbs, the tail, trunk, and head, including whiskers. The tremor is
particularly visible when the animal ambulates, and is less when it lies
down.
The peak tremor frequency varies according to the species, ranging
from 8–10 Hz in monkey to 11–14 Hz in mice.24 After subcutaneous
Figure 1. b-Carboline Structures. Harmaline and harmine are used in
animal models of tremor. Harmane, found in human tissue, can be converted to
harmine.
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or intraperitoneal injection, tremor develops within minutes and lasts
up to several hours before subsiding. Tremor may be assessed with
rating scales,25 electromyographic recordings, or digitally quantified
with systems that detect motion through force or magnetic field
transduction.26,27 Because harmaline-induced tremor is an action
tremor, the amount of tremor will vary according to the motor activity
level. This source of variation can be greatly reduced by normalizing
the data to overall motion.28
Whole-body tremor is dose-dependent with harmaline doses at
4 mg and above26 in rats. Doses of 10–20 mg/kg are frequently
employed in rats; mice require approximately twice that. If rats are
trained to press a disk connected to a transducer, forelimb tremor can
be detected at a dose as low as 1.0 mg/kg.29
Repeated daily administration of harmaline to rats, 4–16 mg/kg,
results in a loss of the tremor response (tolerance) after three to seven
treatments, lasting at least 7–10 days.26,30 In contrast, tolerance is not
observed with four daily doses of a low dose at 1.0 mg/kg,29 or if
tremor is prevented with diazepam or morphine during the initial
exposure.30 Mice also develop harmaline tolerance.24
Inferior olive (IO) neurons in tolerant rats fail to show harmaline-
associated sustained rhythmic activity, and vermal Purkinje neurons do
not show expected rhythmic climbing fiber responses, suggesting that
tolerance may reflect physiological changes.31,32
Another explanation for tolerance may be neuronal damage,
but rats and mice show different morphological alterations after
harmaline. In rats, harmaline causes Purkinje neuron loss in narrow
parasagittal vermis zones, possibly due to excitotoxic climbing fiber
hyperactivity. The IO is unaffected33,34 In contrast, mice show no cell
loss or gliosis in the cerebellar cortex but instead show microgliosis
in IO without cell loss, with the medial and dorsal accessory regions
most affected.34
The anatomic and physiologic basis of harmaline tremor
Harmaline activates circuits within the olivocerebellar system to
produce tremor. Before discussing this circuitry we briefly review
selected aspects of olivocerebellar physiology.
Normal olivocerebellar system functioning
Subthreshold oscillation. IO neurons in brainstem slices normally
demonstrate rhythmic membrane voltage subthreshold oscillations
(STOs) that involve serial ion conductances. A high threshold calcium
spike is followed by a depolarizing shoulder that is terminated by a
potassium conductance that leads to an afterhyperpolarization, which
in turn deinactivates a low-threshold (T-type) calcium current. That
causes a rebound spike which triggers the high-threshold calcium
spike, and may or may not be enough to trigger a sodium spike. The
oscillation frequency is approximately 10 Hz, whereas individual IO
cells fire at 1 Hz.35–38 Spontaneous STOs are suppressed by apamin,
serotonin via 5HT2a receptors,39 NMDA receptor antagonists, and L-,
P-, and T-type calcium channel blockers.40
STOs are synchronized among ensembles of IO neurons via
electrical coupling.35–37,41 Hundreds of IO neurons oscillate coher-
ently in discrete clusters, with moment-to-moment variation in cluster
size. Addition of picrotoxin, a GABAA receptor antagonist, induces
clusters to merge, forming larger units.42 IO neurons form dendritic
tangles (glomeruli) containing abundant gap junctions.43 Addition of
a gap junction blocker disrupts synchrony.44 GABAergic afferents
terminate near gap junctions, where they can control electrotonic
coupling.36
IO–Purkinje ensembles. IO neurons project climbing fibers to Purkinje
cell dendrites, with collaterals to deep cerebellar nuclei (DCN) non-
GABAergic and GABAergic neurons.45 Purkinje cells respond to
climbing fibers with complex spikes, whereas parallel fibers from
granule cells mediate simple spikes. Because each Purkinje cell receives
a single climbing fiber from a dedicated IO neuron, the behavior of
multiple IO neurons in vivo can be studied by recording complex spikes
from many Purkinje cells simultaneously. Such studies reveal that
Purkinje cell firing is synchronized at 10 Hz within small vertical
cortical bands, indicating that they are controlled by electrically
coupled IO ensembles.46 The intra-band synchrony and band size,
and by inference that of the projecting IO ensemble, are not fixed but
modulated by afferents to IO. Intra-IO picrotoxin injection or lesions
of the dentate nucleus, which projects GABA to the IO, increases
Purkinje cell within-band synchrony and synchronous band width.47,48
Glutamate also modulates IO/Purkinje synchrony. Intra-IO injection
of 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfona-
mide (NBQX), an a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic
Figure 2. Recorded Motion. Data are shown for example mouse prior to (A),
and after intraperitoneal harmaline administration (B). The slow recording speed
demonstrates tremor that fluctuates according to general motor activity. The fast
recording speed shows that motion is dominated by tremor at 10-16 Hz. Motion
between 0 and 34 Hz was detected with a load sensor under a platform and
digitized, with filters at 1 and 70 Hz and sampling frequency of 128 Hz.
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acid (AMPA) receptor antagonist, reduces synchronous Purkinje cell
band width, indicating that glutamate expands synchrony in the IO.48
In summary, IO neurons do not fire often, but when they do, the
timing is precisely timed according to the depolarization phase of
STOs that are tightly synchronized within an IO ensemble. The
aggregate firing is thus highly rhythmic. The IO ensembles are not
fixed, but sculpted on a moment-to-moment basis.49 IO gap junctions
and the activity of DCN that control IO coupling via GABA
projections play critical roles.
Gap junctions. IO neurons richly express the gap junction protein
connexin 36 (Cx36).41 Cx36-null mice appear to lack IO gap
junctions,50 and IO slices show rare and weak electrical coupling, so
that IO STOs and action potentials are not synchronized.51 Loss of IO
coupling also occurs with transduction of inactive mutant Cx36 and
the addition of the gap junction blocker carbenoxolone.52,53 Purkinje
cell complex spike synchrony is lost in mice receiving intra-IO
carbenoxolone injection and in Cx36-null mice.54,55
Deep cerebellar nuclei. DCN neurons send excitatory efferents to
extracerebellar structures and a massive GABAergic projection to the
IO. Climbing fibers are excitatory and send collaterals to GABAergic
DCN neurons, which are coupled with Cx36 gap junctions,41 and
project back to IO, and to non-GABAergic DCN neurons. Climbing
fiber-activated Purkinje cells project GABAergic terminals to both
DCN non-GABA (glutamate) and GABAergic neurons.56
GABA DCN neurons show strong rebound discharges after AHP,
due to Cav3.1 T-type channels,57 compatible with phasic firing, in
which timing rather than intensity modulation is important.58 In
contrast, large non-GABA DCN neurons express a linear firing-to-
stimulation relationship, functioning as a linear transducer of spike
frequency, suitable as output neurons. These neurons express weaker
rebound discharges,58 and may correspond to excitatory neurons
observed not to express Cav3.1 T-type channels.57
What happens to this system when harmaline is administered? When
harmaline is added to the brainstem slice, IO neurons exhibit
increased rebound low threshold (T-type) calcium spikes, so that each
rebound is now associated with bursts of sodium action potentials.
Thus the IO neurons are made more excitable by harmaline and
convert from STO to rhythmic 9–12 Hz burst-firing.36,37 In animals,
IO harmaline microinjection elicits rhythmic local bursting only
when the medial accessory olive (MAO) and dorsal accessory olive
(DAO) are injected.59 Intravenous harmaline in cats causes IO
neurons confined to MAO and DAO to fire rhythmically and
synchronously at 6–12 Hz, generating rhythmic Purkinje cell complex
spikes, whereas simple spikes are suppressed.22. In addition, neurons in
DCN, lateral reticular nucleus, red nucleus, nucleus reticularis
tegmenti pontis, spinal cord interneurons, and motoneurons also fire
at the tremor frequency.60,61 In cat, harmaline increases glucose
utilization in the MAO, caudolateral DAO, the molecular layer of
the vermis and paravermis cerebellar cortex, and the same three
brainstem nuclei shown to fire at the tremor frequency.62 Fos
mapping demonstrates IO activation 15 minutes after harmaline
administration, followed by DCN at 30 minutes, cerebellar cortex
at 1 hour, and vertical bands of vermal Purkinje cells at 2–6 hours.63
The delay in DCN recruitment has also been found with field potential
recordings.64
The harmaline-responsive Purkinje cells are mainly found in the
vermis and paravermis regions in the rat and cat,65 to which MAO
and DAO project. These cortical regions project to the fastigial and
interpositus DCN, which also receive climbing fiber collaterals from
MAO and DAO. The DCN send reciprocating GABAergic projec-
tions back to the IO subnuclei. These connections are highly organized
with somatotopic precision.66,67
Climbing fibers are required for tremor expression. The destruction of
IO by systemic 3-acetylpyridine injection eliminates the tremor
response.68 If the cerebellar peduncles are cut to sever climbing fibers,
the MAO and DAO still show bursting and increased glucose
utilization by harmaline, whereas Purkinje cell and fastigial nucleus
bursting is abolished, and metabolic activation of other medulla
structures fails to occur.22,61 The importance of climbing fibers is
also illustrated in genetically dystonic rats, which do not show normal
climbing fiber-induced complex spike responses.69 On harmaline
administration, IO neurons but not Purkinje cells, fire rhythmically,
and tremor does not occur.32,70
Are Purkinje cells required for tremor? Cooling of the cerebellar cortex
does not abolish harmaline-induced motoneuron firing, suggesting
that the olivo–DCN loop may be sufficient for tremor.61 Mice with
Purkinje cell degeneration (pcd) still manifest harmaline tremor despite
the complete absence of Purkinje cells, although the tremor is of lower
frequency and amplitude than controls. Lurcher mice also have no
Purkinje neurons, but mount no harmaline tremor. The difference
between these two strains of mice is that pcd mice have intact climbing
fibers capable of contacting DCN neurons, whereas lurcher mice
appear not to.71
What is the role of DCN in tremor? DCN neurons, as the sole output of
the cerebellum, are required for the expression of harmaline tremor.
On the other hand, lesions of the dentate nucleus or DCN outflow
pathways are well known to induce action tremor in humans,72 and
lesions or inhibitory injections of the interpositus nucleus or
combined lesions of interpositus and dentate nucleus can induce
action tremor in monkeys.73–75 Thus DCN paradoxically can
express and suppress tremor. On adding harmaline to a guinea
pig cerebellum–brainstem in vitro preparation, one group of DCN
neurons responds with an excitatory post-synaptic potential, an
inhibitory post-synaptic potential (IPSP), then a rebound discharge,
whereas another group responds with an initial IPSP followed by a
rebound discharge. These responses have been interpreted to
indicate that harmaline induces phasic rhythmic activity in
excitatory DCN output neurons, thereby expressing tremor, and in
inhibitory nucleo-olivary neurons, thereby modulating rhythmicity
and synchronicity.76
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Are the brainstem and spinal cord sufficient for harmaline tremor? Cooling
of the motor cerebral cortex and lesions of the ventrolateral thalamus
or globus pallidus reportedly do not affect harmaline tremor in intact
monkeys.77,78 Not even intercollicular decerebration abolishes tremor
in cats or monkeys.78,79 These observations suggest that the brainstem
and spinal cord are sufficient to express harmaline tremor, even in
primates. On the other hand, high-frequency stimulation simulating
deep brain stimulation (DBS) of the ventrolateral thalamus, and
intrathalamic infusion of muscimol or an adenosine A1 receptor
agonist suppress harmaline tremor in mice,80 indicating a potential
role of the thalamus in modulating harmaline tremor.
Summary. Harmaline induces rhythmic bursting in accessory IO
neurons that then recruits medial regions of cerebellar cortex and
DCN. The end result is rhythmic activation of the spinal gamma and
alpha motoneurons and tremor.
Proposed mechanisms of harmaline tremor
Here we consider the question how harmaline acts at the cellular
level to induce tremor.
Serotonin. Initial ligand binding studies indicated that harmaline
does not bind significantly to 5-hydroxytryptamine (HT)1a-d, 5-HT2 or
5-HT3 receptors (Ki.100 mM).
81 Subsequently harmaline was found
to have affinity to the 5-HT2a (Ki57.8, 42.5 mM) and 5-HT2c
(Ki59.4 mM) receptors,
82,83 comparable to the cerebellar harmaline
level of 18.2 mM after 15 mg/kg in mice.84 Acting through 5-HT2a
receptors, intra-IO 5-HT injection increases IO neuronal firing rates
and improves coherence, while increasing intra-band Purkinje cell
synchrony, similar to harmaline, but harmaline’s action is not blocked
by a 5-HT2a antagonist.
85
NMDA receptor channel. Harmaline competitively displaces tritiated
MK801 (dizocilpine) from the NMDA receptor in rabbit IO fractions
(IC50 60 mM),
86 leading to the suggestion that harmaline induces
tremor by acting as an NMDA receptor inverse agonist. However this
action would produce depolarization, whereas harmaline hyperpo-
larizes IO neurons.
Benzodiazepine receptor. Harmaline displaces tritiated flunitrazepam
from brain tissue only at high IC50 concentrations: 126–600 mM.
84,87
The benzodiazepine antagonists flumazenil and CGS8216 do not
affect harmaline tremor in mice.88 Moreover, binding of 3H-
flunitrazepam in IO of adult rodents is very sparse.89 Harmaline is
thus not likely to induce tremor via benzodiazepine receptors.
Sodium and high-voltage calcium conductances. Harmaline does
not significantly displace ligands at adrenergic, dopamine, opiate,
muscarinic, nicotinic, GABA receptors or the chloride channel. An
affinity for the voltage-gated sodium channel, (Ki513.9 mM), suggested
this as a potential mechanism of tremor.81 However, very high levels of
harmaline are needed to affect the action potential (.0.5 mM).90 At
100 mM, harmaline inhibits sodium conductance by 23% in dorsal
root ganglia neurons. High-voltage calcium channels (L- and N-type)
are more sensitive, with an IC50 by harmaline of 100 mM. However
harmane, which is less tremorigenic, is more potent (IC50576 mM),
91
thus this channel is not likely to mediate tremor.
The Cav3.1 T-type calcium channel. IO slices from Cav3.1-null mice
fail to show STOs or low-threshold calcium spikes. Harmaline fails to
produce rhythmic firing in IO slices from Cav3.1 null mice.64 Park
et al.64 studied harmaline effects on Cav3.1 currents in vitro and found
a complex set of actions that in combination leads to enhanced
rebound spikes. They postulate that harmaline engenders tremor by
effects on the Cav3.1 channel.64 Effects on Cav3.2 or Cav3.3 channels
were not studied.
Other actions. Harmaline inhibits sodium-dependent transport of
substances into various tissues, such as choline into striatal synapto-
somes (Ki536 mM),
92 and gamma-hydroxybutyrate into whole-brain
synaptosomes (Ki594 mM).
93 Harmaline is a potent inhibitor of
MAO-A, with IC50 values as low as 4–8 nM. Activity against MAO-
B is negligible.94 Harmaline inhibits synaptosomal GABA uptake
(IC50 47 mM)
95 and dopamine uptake (IC5058.1 mM),
96 and increases
dopamine release from striatal slices at 6 mM.94 Low doses enhance
levodopa-induced stereotypy in mice.97 These observations are com-
patible with reports that Parkinson’s motor symptoms are ameliorated
by extracts of B. caapi.94
Harmaline also potently inhibits cerebral histamine N-methyltrans-
ferase (IC5054.4 mM), which may raise histamine levels,
98 and dis-
places tritiated tryptamine is brain tissue (IC50525 nM).
99 Harmaline
potently binds the imidazoline 2B receptor (Ki5177 nM).
100
Summary. Several potential mechanisms by which harmaline could
produce tremor have been investigated. At present the most likely
mechanism appears to be modulation of T-type calcium channels. It is
not clear whether this action is restricted to Cav3.1 channels or also
involves Cav3.2 and Cav3.3. Harmaline is a potent inhibitor of MAO-
A, and has significant effects on dopamine and histamine processing.
The pharmacology of harmaline tremor
Serotonin (5-HT). Serotonergic fiber innervation in IO is highest
in caudal MAO and caudolateral DAO, correlating with high
sensitivity to harmaline-induced rhythmicity.101,102 Lesions of 5-HT
fibers to the IO, or of the medial and dorsal raphe nuclei, reduce the
harmaline tremor response.101,103 The genetically epilepsy-prone rat
(GEPR) has reduced serotonergic IO innervation, and manifests
poor harmaline tremor.104 Harmine tremor is exacerbated by the 5-
HT precursor 5-hydroxytryptophan,103 an effect reduced by raphe
lesions.103 Conversely, the broad-spectrum 5-HT antagonist methy-
sergide and the 5-HT synthesis inhibitor para-chlorophenylalanine
reduce harmaline tremor.105,106 The serotonin uptake inhibitor
citalopram (10–40 mg/kg) enhances harmaline tremor in rats,107 as
does imipramine.106
Norepinephrine. When norepinephrine is added to guinea pig
brainstem slices, harmaline-induced rhythmic IO oscillations ceases.37
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Systemic injection of the norepinephrine precursor L-threo-3,4-
dihydroxyphenylserine (L-threo-DOPS, 50–200 mg/kg) suppresses
harmaline tremor in rats.108 Intraventricular L-threo-DOPS also
suppresses harmaline tremor, as does electrical stimulation of locus
ceruleus.109 In contrast, the tyrosine hydroxylase inhibitor alpha-
methyl-p-tyrosine, 200 mg/kg; 6-hydroxydopamine injections that
reduce cerebellar norepinephrine; and locus ceruleus destruction
each exacerbate harmaline tremor.108–110
Beta-adrenergic blockers such as propranolol suppress harmaline
and harmine tremor in rodents.111,112 Selective beta1- and beta2-
adrenergic antagonists can each suppress harmaline tremor in rats,
but beta2-blockade may be more effective.
113 Although propranolol
may act in part peripherally,113 it also acts directly by antagonizing
the electrophysiological effects of harmaline on IO neurons in
brainstem slices.114 In contrast, the alpha-adrenergic antagonist
phenoxybenzamine does not suppress harmine tremor,115 and is
ineffective for ET.116
Glutamate. Intracisternal 2-amino-5-phosphonovalerate (2-APV), an
NMDA receptor antagonist, suppresses harmaline tremor in mice.115
Similarly the competitive NMDA antagonist d-CPPene suppresses
harmaline tremor in mice and rats.117,118 The non-competitive
NMDA antagonist dizocilpine (MK-801) potently suppresses harma-
line tremor in mice and rabbits,118,119 as does phencyclidine in
mice.118 Memantine has only a weak antitremor effect in rats,120
comparable to a weak or non-existent effect on ET.121 However,
memantine confers striking protection against harmaline-induced cell
loss in the cerebellum and IO.120
The AMPA receptor antagonist RPR117824 suppresses harma-
line tremor,122 as does NBQX disodium salt.118
The mGluR1 antagonist JNJ 16259685-a strongly enhances
harmaline tremor in rats, suggesting an agonist at this receptor should
suppress tremor.123 In contrast, the mGluR5 receptor antagonist 6-
methyl-2-(phenylethynyl)pyridine (MPEP) has no effect in mice.118
GABA. The benzodiazepine diazepam, 1.5–5 mg/kg, suppresses
harmaline tremor in rodents.88,124 The GABAA receptor agonist
muscimol also suppresses harmaline tremor in mice.118 The GABAB
receptor agonist baclofen, 2.5–10 mg/kg, dose-dependently suppress
harmaline tremor in rats,125 and reduces harmine tremor in alcohol-
withdrawing rats.126 However Paterson et al.118 did not find tremor
suppression by baclofen in mice.
Dopamine (DA). Harmine tremor is reduced by levodopa and by the
agonists apomorphine and piribedil in rats and mice.103,118 Similarly
the dopamine uptake inhibitor GBR12909 reduces tremor.118
Apomorphine is a D1/D2 agonist. Tremor is not reduced by the D1
agonist SKF82958, but is by the D2/D3 agonist quinpirole.
118
Alcohol. Suppression of harmaline tremor by ethanol has been well
replicated,28,127 but the site of action and mechanism remain unclear.
Ethanol reduces harmaline tremor in mice at low doses that do not
suppress harmaline-induced cerebellar cyclic GMP elevations.127 This
observed dissociation between ethanol’s climbing fiber-mediated and
behavioral effects raised the possibility of an extra-olivary localization
of the antitremor action. In rats anesthetized with agents other than
urethane, or immobilized and given local anesthesia, ethanol increases
IO firing rates.128 A moderate ethanol dose (1 g/kg) increases vermal
Purkinje cell complex spike rhythmicity and synchrony in ketamine-
anesthetized rats, and by inference IO ensemble rhythmicity and
synchrony. Moreover ethanol fails to affect the rhythmicity of
harmaline-induced complex spike activity.129 These observations
suggest that alcohol does not suppress but instead increases IO firing
with potentially excitotoxic effects. This inference is supported by the
finding that although ethanol, 1.5 g/kg, effectively suppresses tremor
in rats, histology 24 hours later reveals that ethanol-treated rats
display an exacerbation of the harmaline-associated vermal and
paravermal Purkinje and granule cell loss, and more IO neuronal
loss.120 Conceivably alcohol’s antitremor efficacy may lure ET patients
to alcohol-exacerbated cerebellar damage, to which they may be more
vulnerable.
Antiepileptic drugs. De Ryck et al.130 found antitremor effects for
primidone, clonazepam, gabapentin, and carbamazepine. Whereas
levetiracetam had minimal effect on tremor, the derivative brivar-
acetam was effective. Similarly, Paterson et al.118 found that
primidone, gabapentin, and carbamazepine suppress harmaline
tremor in mice, but also reported that valproate does as well.
Zonisamide suppresses harmaline tremor in mice, with 50 mg/kg
more effective than 5 mg/kg.25 Zonisamide has shown efficacy for
ET.131 Lacosemide, 0.3–30 mg/kg, suppresses harmaline tremor in
rats;132 however, a clinical trial did not show efficacy for ET.133
Similarly, carisbamate suppressed harmaline tremor in preclinical
testing, but demonstrated no antitremor efficacy in an ET trial.134
Gap junction blockers. Contrary to expectation, Cx36-null mice or
mice with IO transduction of inactive mutant Cx36 mount a vigorous
tremor response to harmaline.51,52 On the other hand, harmaline
tremor is suppressed by the broad-spectrum gap junction blocker
carbenoxolone and by more specific mefloquine.135 It may be con-
jectured that other gap junctions also play a role in harmaline tremor,
such as connexin 57.136 More research on this topic is warranted.
T-type calcium channels. Isomers of octanol suppress harmaline tremor
in the rat.137 Because octanol blocks T-type calcium channels it was
predicted that antagonists of these channels could be effective for
tremor. However, octanol exerts multiple actions. We showed that
each of five drugs that block T-type calcium channels suppress tremor
in the harmaline model and in the GABAA a1-null genetic mouse
tremor model.138 The best agent appeared to be NNC55-0396.139,140
Of the three subtypes of T-type calcium channels, Cav3.1 is
expressed in IO, Purkinje cells and some DCN neurons. Park et al.64
reported that Cav3.1-null mice generated in the laboratory of HS Shin
are impaired in manifesting harmaline tremor. This was demonstrated
with a low harmaline dose that in wild-type mice induced tremor for
only 15 minutes. Tremor was greatly reduced in Cav3.1-null mice, but
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not abolished.64 Although these authors postulate Cav3.1 is the
‘‘pacemaker’’ for tremor, they do not explain how harmaline is able to
induce any tremor in Cav3.1-null mice. Our laboratory found that a
routine dose of harmaline that results in longer tremor produces as
much tremor in Cav3.1-null mice generated by K Sakimura as in wild-
type mice. Moreover, NNC55-0396 suppresses tremor in the Cav3.1-
null mice.138 As NNC55-0396 may act on Cav3.2 and/or Cav3.3
channels as well as Cav3.1, it is possible harmaline has an effect on
these subtypes, although such a role in tremor remains unexplored.
Adenosine. Harmaline tremor is enhanced by the adenosine receptor
antagonist caffeine, 50–150 mg/kg, in rats,141 and by the A1 receptor
antagonist 8-cyclopentyl-1,3-dipropylxanthiine (DPCPX), 4 mg/kg,
in mice.80 Intrathalamic infusion of adenosine or the A1 receptor
agonist 2-chloro-N6-cyclopentyladenosine reduces harmaline tremor.
Infusion of DPCPX or the use of A1 receptor null mice reduces
the threshold for DBS-induced involuntary movements (related to
glutamate release), so that tremor cannot be suppressed by DBS.
Thalamic DBS is suggested to cause local adenosine release that limits
glutamate effects, enabling tremor to be suppressed at current levels
below those associated with involuntary movements.80
Other drugs. Anticholinergics do not reduce harmine tremor in
rodents.111 Harmaline tremor is suppressed by systemic lidocaine
(12.5–50 mg/kg);142 dantrolene, 10 mg/kg;124 lithium, 2 mEq,118 in
mice; and 16-methyl-prostaglandin E2 (PGE2), 25–50 mg/kg, in
cats.143 Conversely, harmine tremor is enhanced by cyclosporin, 25–
50 mg/kg, in mice.144 MK-0249, a histamine-3 receptor inverse
agonist, suppresses harmaline tremor, but does not suppress ET
tremor.145
Summary. Knowledge of the physiology and the basic circuit of
harmaline tremor (Figure 3) suggests that drugs affecting specific ion
conductances, such as the T-type calcium channel, gap junctions,
glutamate, and GABA receptors should affect tremor; notions that
have received support. In addition, the tremorigenic circuit is
susceptible to influence by various neurotransmitter systems, including
norepinephrine, 5-HT and DA. Further research is likely to reveal
more neuromodulators of tremor.
Harmaline tremor as a preclinical model of ET
Comparison with ET. Harmaline-induced tremor has been suggested
as useful for preclinical screening of potential ET therapies. ET and
the harmaline animal model differ in a number of respects, however,
and the harmaline model possesses limitations.
Harmaline tremor is an acute state induced pharmacologically,
following which animals are resistant to further doses. In contrast,
ET develops gradually, and is chronic, without remission. Based on
associations of lower risk for ET with smoking and a Mediterranean
diet,13,146 and findings of Purkinje cell loss with cerebellar cortical
gliosis or locus ceruleus depletion and/or Lewy bodies, it appears likely
that at least in some cases ET is a neurodegenerative disorder.147
Harmaline acts on the IO to produce tremor. In ET, the role of IO
is less certain. In ET subjects, eye-blink conditioning, which depends
on the olivocerebellar pathway, is impaired.148 One imaging study
found increased glucose utilization in the IO region in ET,149 but
another study found no change in IO blood flow.150 Cerebellar cortical
hypermetabolism, known to depend in the harmaline model on
climbing fiber activation, also occurs in ET.149–151 Interestingly,
alcohol administration suppresses cerebellar hypermetabolism in ET
subjects, and increases IO blood flow, which does not happen in
controls, suggesting that IO physiology differs in ET.151
Each pharmacotherapy suppresses tremor in only a fraction of ET
patients. Given ET’s heterogeneity, it is uncertain to what extent
harmaline or any other animal model can offer predictive success.
Another caveat in comparing drug efficacy for harmaline vs. ET is
that, based on published reports, it is difficult to assess to what extent
suppression of harmaline tremor is a non-specific effect of sedation
or reductions in motor activity. Potential approaches are to employ
tremor measures that are insensitive to locomotor activity levels, and
to select doses shown in independent behavioral tests not to affect
motor activity.
How accurate is the harmaline model in predicting efficacy for ET? An
initial prediction was encouraging. Sinton et al.137 reported in 1989
that isomers of octanol suppress harmaline tremor in the rat,
subsequently replicated in mice.135 Early-stage clinical trials later
demonstrated that 1-octanol reduces tremor in ET.152 In humans,
Figure 3: The Olivocerebellar Circuit Implicated in the Generation
and Expression of Harmaline Tremor. Synaptic bar endings connote
inhibition, while arrowhead endings connote excitation. Harmaline elicits
rhythmic bursting in clusters of inferior olivary neurons, synchronized via
dendritic glomeruli. Climbing fibers excite complex spikes in Purkinje cells, which
project GABA to both GABAergic and excitatory output deep cerebellar nucleus
cells. These cells also receive collaterals from climbing fibers. The deep cerebellar
nuclei project GABA to inferior olivary glomeruli, opposing synchrony. Glutamate
receptor activation in the inferior olive promotes synchrony. The deep cerebellar
nuclei and inferior olive are required for harmaline tremor expression; the absence
of Purkinje cells reduces but does not abolish tremor. The deep cerebellar outflow
to the brainstem and spinal cord is sufficient for harmaline tremor expression
without the need for supratentorial structures.
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1-octanol is rapidly converted to octanoic acid, which may be the
active antitremor agent.153
Citalopram, imipramine and caffeine worsen both harmaline107,143
and ET tremor (Table 1). We do not know of any agent that fails to
suppress harmaline tremor yet is effective for ET. Phenoxybenzamine,
levetiracetam, and anticholinergics do not suppress harmaline tremor,
and do not usually suppress tremor in ET.
Of 16 agents reported to suppress harmaline tremor, including weakly
effective memantine, seven fail to suppress ET tremor, including several
anti-epileptic drugs,133,134,154 levodopa and dopamine agonists,103
Table 1. Comparison of Harmaline Rodent Tremor Model and Essential Tremor
Feature Harmaline Tremor Essential Tremor
Clinical
Action tremor Yes Yes
Time course Acute Chronic
Inducing agent Pharmacologic Probably neurodegenerative
Role of inferior olive Definite Uncertain
Cerebellar hypermetabolism Yes Yes
Response to drugs
Caffeine Worsens Worsens in some
Citalopram, imipramine Worsens Worsens in some
Phenoxybenzamine Does not suppress Does not suppress
Anticholinergics Do not suppress Do not suppress
Levetiracetam Does not suppress Does not suppress
Primidone Suppresses Suppresses in some
Clonazepam, diazepam Suppresses Suppresses in some
Gabapentin Suppresses Suppresses in some
Carbamazepine Suppresses Does not suppress
Valproate Suppresses Does not suppress/worsens
Zonisamide Suppresses Suppresses in some
Lacosamide Suppresses Does not suppress
Carisbamate Suppresses Does not suppress
Propranolol Suppresses Suppresses in some
L-dopa, DA agonists Suppresses Do not suppress
Ethanol Suppresses Suppresses in some
Gamma-hydroxybutyrate Suppresses Suppresses in some
Lithium Suppresses Does not suppress/worsens
1-Octanol Suppresses Suppresses in some
Memantine Weakly suppreses Weak or no suppression
MK-0249 Suppresses Does not suppress
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lithium,118 and MK-0249. Matches between positive results in the
harmaline model and efficacy in ET trials occurred in 9 out of 16 agents
or a 56% concordance rate, and include propranolol, several anti-
epileptic drugs, alcohol, memantine, and gamma-hydroxybuty-
rate.118,155 Because some of these agents were tested in the model after
having been found effective in ET, the true predictive success rate for the
model may be lower than 56%.
Summary. As is often the case with neurological disease models, the
harmaline model is prone to false positives. Because the harmaline
state is poorly compatible with sensitive tests of drug intoxication,
independent tests of behavioral tolerability in non-harmaline control
subjects may be appropriate.
Conclusion
Like ET, harmaline induces an action tremor that involves
cerebellar circuitry, and responds to drugs that suppress clinical
tremor. Unlike ET, harmaline tremor is acute and temporary.
Harmaline converts IO STOs to rhythmic burst firing that is
propagated through the cerebellum, then ultimately activates spinal
motoneurons to express tremor. The minimum cerebellar circuit
required includes the IO, climbing fibers and DCN. Pharmacologic
studies indicate that harmaline tremor severity is influenced by several
glutamate receptors, GABA A and B receptors, serotonin receptors,
norepinephrine receptors, dopamine receptors, gap junctions, T-type
calcium channels, alcohol, and antiepileptic drugs. Of drugs that
suppress harmaline tremor, approximately half suppress ET tremor.
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